The largest holder of Moderna stock is Fidelity Management & Research Co. LLC, with 51.9 million shares (12.99% of the company), worth about $7.28 billion as of September 25, 2026. The 10 largest holders together own 53.4%.
In Q2 2026, 873 institutional holdings reports listed 346.0 million shares worth $22.70 billion, up 12.3% in shares from Q1 2026.
Insiders reported 83 transactions in the last two years: 14 sales worth $12.30 million and 2 purchases. The newest one on file is from May 15, 2026 (Hoge Stephen, President).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 15, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Fidelity Management & Research Co. LLC | 51.9 million | 12.99% | $7.3B |
| BlackRock Advisors LLC | 25.1 million | 6.28% | $3.5B |
| Vanguard Capital Management LLC | 23.2 million | 5.81% | $3.3B |
| Capital Research & Management Co. (World Investors) | 22.3 million | 5.58% | $3.1B |
| Stéphane Bancel5.565 % | 22.2 million | 5.57% | $3.1B |
| Baillie Gifford & Co. | 18.2 million | 4.56% | $2.6B |
| State Street Corporation | 15.7 million | 3.94% | $2.2B |
| Vanguard Portfolio Management LLC | 15.6 million | 3.90% | $2.2B |
| Geode Capital Management LLC | 9.7 million | 2.43% | $1.4B |
| Eaton Vance Management | 9.5 million | 2.39% | $1.3B |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 873 | 346.0 million | $22.7B |
| Q1 2026 | 807 | 308.0 million | $15.6B |
| Q4 2025 | 764 | 305.0 million | $9.0B |
| Q3 2025 | 737 | 277.0 million | $7.2B |
| Q2 2025 | 761 | 303.0 million | $8.4B |
| Q1 2025 | 779 | 282.0 million | $8.0B |
| Q4 2024 | 849 | 277.0 million | $11.5B |
| Q3 2024 | 894 | 265.0 million | $17.7B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Hoge Stephen | May 15, 2026 | President | Conversion of Exercise of derivative security at price 19.15 per share. | $1.0M |
| Hoge Stephen | May 15, 2026 | President | Sale at price 48.40 per share. | $2.6M |
| Hussain Shah Abbas | May 1, 2026 | Director | Sale at price 46.63 per share. | $264,952 |
| Hussain Shah Abbas | Apr 30, 2026 | Director | -- | – |
| Tallett Elizabeth E | Apr 30, 2026 | Director | -- | – |
| Rubenstein David M | Apr 30, 2026 | Director | -- | – |
| Nabel Elizabeth G | Apr 30, 2026 | Director | -- | – |
| Horning Sandra | Apr 30, 2026 | Director | -- | – |
| Nader Francois E. | Apr 30, 2026 | Director | -- | – |
| Mock James M | Apr 2, 2026 | Chief Financial Officer | -- | – |
| Klinger Shannon Thyme | Mar 5, 2026 | Officer | -- | – |
| Mock James M | Mar 5, 2026 | Chief Financial Officer | -- | – |
Newest 12 of 83 insider transactions in the last two years.
Fidelity Management & Research Co. LLC, with 12.99% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (6.28%) and Vanguard Capital Management LLC (5.81%).
873 institutional holdings reports listed Moderna shares in Q2 2026, 346.0 million shares in all worth $22.70 billion.
In the last two years insiders reported 14 sales and 2 purchases (83 transactions in all); the newest on file is from May 15, 2026.